5 FAQs About CDC Opioid Prescribing Guidelines and Clinical Impact

The CDC’s Opioid Prescribing Guidelines initially stirred a significant amount of controversy among health care organizations, health systems, and clinicians when they were first published in 2016.¹ They were then updated in 2022 to broaden the patient scope and recommendations on dose, durations, tapering, and discontinuations.

Aimed at managing the ongoing opioid epidemic, the CDC created the guidelines to direct care strategies and mitigate the risk of opioid overdose. The overall overdose death rate in the US has skyrocketed since 1999. As of 2023, the overdose death rate was nearly 10 times what it was in 1999. Although overall deaths from overdoses have continued to rise, the rate of deaths from opioid prescriptions, specifically, decreased by nearly 12% from 2022 to 2023, according to the most recent CDC data.¹

These data highlight the need for efforts like the CDC’s opioid prescribing guidelines that instruct care providers on ways to reduce the risk of opioid overdose death.

Here are 5 FAQs about the updated CDC opioid prescribing guidelines.

1. How should health plans operationalize the CDC opioid prescribing guidelines?

The CDC’s opioid prescribing guidelines were designed to address the ongoing opioid epidemic in the US by suggesting overdose risk–based assessments and encouraging alternative therapies to reduce death by prescription opioid use. Health plans can operationalize these guidelines, not by making opioids harder to access, but by using them to align formularies, prior authorization criteria, and step therapy requirements.

“From a physician or provider group or a health care agency or group perspective, the goal isn't to develop something that's absolutely prescriptive, because health care providers recognize and understand that there is enormous variability amongst individuals,” Michael Lynch, MD, FACMT, an associate professor of emergency medicine at the University of Pittsburgh School of Medicine, said in an interview with The American Journal of Managed Care^® (AJMC^®).

As research on prescribing patterns and dosage continues to evolve, so should the health policies, guidelines, and health plans that support them, Kerry Schwarz, PharmD, MPH, senior clinical manager of evidence-based medicine at Vizient, said in an interview with AJMC, noting that the update was also in part due to new evidence within the landscape.

“I think these are steps towards approaches that are more individualized while still being evidence- and experience-based,” she said.

2. Are dosage thresholds in the CDC guidelines intended to be hard limits?

The CDC guideline dosage thresholds are suggestions to guide treatment but are not hard limits. However, multiple health care organizations, states, and physicians have incorrectly cited the 2016 guidelines as mandates rather than suggestions, potentially negatively impacting some patient outcomes.¹ A cap of 90 morphine milligram equivalents (MME) a day is recommended, as exceeding that dosage increases the risk of opioid overdose, Jim Lichauer, PharmD, BCPS, FASHP, senior performance improvement program director of pharmacy at Vizient, said in an interview with AJMC.

“Initially, those limits created some barriers or obstacles and also hindered some physicians from prescribing,” Lichauer said. “I think we got to a point where we were able to understand how to provide the resources and structure to provide and evaluate the risk vs benefit.”

Since then, the 2022 update has emphasized that the guidelines “provide recommendations only,” and they do not replace physicians’ clinical judgment.

The updated guidelines include 12 recommendations varied over 4 different categories tailored to patients’ circumstances. They suggest starting with the lowest effective dose for patients with acute, subacute, or chronic pain on initiation and gradually increasing the dose according to the patient’s pain, comorbidities, age, and any ongoing treatments. However, the decision to prescribe doses higher than 50 MME per day for all patients should be supported with strong justification and monitored, as the risk of overdose increases with increasing dosages.²

3. How should clinicians approach tapering opioids under the updated guidelines?

Before the guidelines were updated in 2022, patients were often experiencing harm from potentially inappropriate tapering of opioids in response to the “dose-based limits” in the 2016 version of the guidelines. Clinicians interpreted the considerations as mandates, often capping patients at less than 90 MME or 50 MME and dramatically reducing their dose if it was higher than recommended.¹

“Folks were tapered quickly; specific [MME] per day were thought to be required to be met, and if those weren't met, they were thought to be inappropriate doses and so forth, not by some taking into account historical precedent, like doses people had been on,” Lynch said.

Yet, when used as a tool to guide physicians’ clinical decisions as a risk-benefit assessment, Lynch says that he has seen fewer people prescribed higher doses of opioids, but still acknowledges the small subset of people who may need it chronically.

“But we hope to see that be a smaller subset without sacrificing management of pain and optimizing people's quality of life,” he said.

4. What are the best practices for ongoing patient monitoring during opioid therapy?

The 7th recommendation in the guidelines is dedicated to evaluating the benefits and risks of starting patients on opioid therapy and those on continued opioid therapy. Within that, there is a heavy emphasis on patient monitoring at follow-up intervals. For example, for patients newly starting extended-release/long-acting opioids of less than 50 MME a day, the initial follow-up should be within 1 to 4 weeks of initiation.

For ongoing monitoring of chronic opioid use, the guidelines suggest an assessment every 3 months and even more frequently for high-risk patients, especially those taking more than 50 MME a day. The assessments should include, but are not limited to, patients’ pain and function, any adverse events, signs of opioid use disorder, patient preference, and mental health status.²

There is still more research needed to cultivate more ideal pain management strategies, Lynch said.

“Understanding that an individual's pain is not always easy to contextualize into a group of similar people,” he said. “That's true in medicine in general, but I think with time, what we hope to see is more upfront management and addressing of the underlying contributors to acute and subacute pain as it potentially transitions to chronic pain.”

5. How can managed care organizations align coverage policies with the CDC guidelines without restricting access?

Managed care organizations can align coverage with the CDC guidelines by avoiding rigid policy interpretations and instead supporting flexible, patient-centered care. Early misapplication—such as hard dose limits or forced tapering—created access barriers and safety concerns, underscoring the need for more nuanced implementation.

“Misunderstanding the guidelines as hard limits did hinder many physicians and/or impact patients, as we better understood the intent of the guidelines,” Lichauer said. “We put into place additional strategies to minimize the risk of opiate overdose, such as dispensing naloxone to everyone who was receiving chronic opiates, and some states even went forward to mandating that.”

Health plans should focus on aligning utilization management with guideline intent: supporting clinician judgment, enabling access to nonopioid therapies, and integrating monitoring rather than restricting prescribing outright. The 2022 update reinforces that recommendations are not mandates and should preserve individualized decision-making and shared clinician-patient discussions.

References

1. McCrear S. The 10th anniversary of the CDC’s opioid prescribing guidelines: new evidence and patient-centered decisions. AJMC. March 24, 2026. Accessed April 21, 2026. https://www.ajmc.com/view/the-10th-anniversary-of-the-cdc-s-opioid-prescribing-guidelines-new-evidence-and-patient-centered-decisions

2. 2022 CDC clinical practice guideline at a glance. CDC. May 7, 2024. Accessed April 22, 2026. https://www.cdc.gov/overdose-prevention/hcp/clinical-guidance/index.html